Apogee Therapeutics, Inc. (NASDAQ:APGE) Shows Strong Balance Sheet While Near-Term Momentum Weakens
Apogee presents a robust liquidity profile alongside clinical progress, but short-term technical signals and momentum measures point to downward pressure on price. Valuation metrics and negative operating results frame the near-term risk profile.








